2021
13/05/2021
Study demonstrates major economic health benefit of PromarkerD – PromarkerD reimbursement update
30/04/2021Proposed issue of Securities
30/04/2021Issue of Options and Secondary Trading Notice
29/04/2021Appendix 4C – March 2021 Quarterly Update
29/04/2021Proteomics files US FDA 513(g) regulatory submission
23/04/2021Proteomics International achieves ISO 13485 certification
15/03/2021Exercise of Options
09/03/2021Investor Presentation
26/02/2021Exercise of Options
25/02/2021Appendix 4D and Interim Financial Report
16/02/2021Response to Price Query
08/02/2021Proteomics International seeks FDA approval for PromarkerD
28/01/2021Update – Proposed issue of Securities – PIQ
28/01/2021Issue of Options and Secondary Trading Notice
28/01/2021Results of Meeting
28/01/2021Appendix 4C – December 2020 Quarterly Update
